7 4
Other processes that are not as well described as genetic hallmarks of B-NHL included BCL6 1 7 5 function and the ubiquitin proteasome system (UPS). Genes associated with BCL6 function 1 7 6 encompassed BCL6 itself and its interacting proteins (BCL6, TBL1XR1, BCOR, SPEN), 1 7 7 regulators of BCL6 activity or expression (MEF2B, IRF8, IRF4), and a critical BCL6 target gene 1 7 8 (PRDM1). Recurrent mutations of the NCOR1 and NCOR2 genes that encode BCL6 co-1 7 9
repressor proteins were also observed ( Figure S4D -E), but were not significant by MutSig2CV. 1 8 0 Multiple recurrently mutated chromatin modifying genes have also been implicated in BCL6 1 8 1 function and therefore also contribute to this hallmark, including CREBBP and EZH2 42, 43 . The 1 8 2 recurrently mutated UPS genes included the CDC27 gene, which encodes an E3 ligase for 1 8 3 CCND1 44 that is mutated in 14% of MCL and has not been previously described in the literature. 1 8 4
The TMEM51 gene was also identified as a novel recurrently mutated gene in 9% of BL, though 1 8 5 the function of this gene is poorly defined. The cross-sectional analysis of multiple lymphoma 1 8 6 subtypes therefore identified conserved hallmarks that are recurrently targeted by somatic 1 8 7 mutations in B-NHL. 1 8 8 1 8 9 Enrichment of functional hallmarks by structural alterations 1 9 0
The hybrid capture probes utilized in our design also targeted recurrent breakpoint regions in 1 9 1 the immunoglobulin heavy-and light-chain loci, as well as the regions of recurrent breakpoints 1 9 2 in or near the BCL2, MYC and BCL6 genes. Translocations were called using a method that 1 9 3 detects discordantly mapped reads 34 and our prior validation of this approach in cases with 1 9 4 matched fluorescence in situ hybridization (FISH) data for MYC showed that it is 100% specific, 1 9 5 but only ~40% sensitive for translocation detection 12 . In addition, we failed to detect CCND1 1 9 6 translocations using this approach. However, we did observe a significantly higher fraction of 1 9 7 BCL6 translocations (57% [27/47]) partnered to non-immunoglobulin loci (eg. CIITA, RHOH, 1 9 8 EIF4A2, ST6GAL1; Table S7 ) compared to BCL2 (1% [1/114]) and MYC (5% [2/38]) 1 9 9 translocations (Figure 2A ; Fisher P-value <0.001). These were more frequent in FL (88% 2 0 0 [15/17] of BCL6 translocations) as compared to DLBCL (39% [9/23] of BCL6 translocations), 2 0 1 presumably because the two immunoglobulin loci in FL are either translocated with the BCL2 2 0 2 gene or functioning in immunoglobulin expression 45 . We also employed off-target reads to 2 0 3 detect DNA copy number alterations (CNAs) in a manner akin to low-pass whole genome 2 0 4 sequencing, identified significant peaks of copy gain and losses using GISTIC2 37 (Figure 2A ; 2 0 5 Figure S5 ; Table S8 -9), and defined the likely targets of these CNAs by integrative analysis of 2 0 6 matched gene expression profiling (GEP) data from 290 tumors (Figure 2B -C, Figure S5 , Table  2 0 7 S10-11). This identified known CNA targets (Figure 2D) , including but not limited to deletion of 2 0 8 TNFAIP3 (6q24.2) 46 , ATM (11q22.3) 47 , B2M (15q15.5) 48 and PTEN (10q23.21) 49 , and copy gain 2 0 9 of REL and BCL11A (2p15), and TCF4 (18q23) 50 . In addition, we identified novel targets such 2 1 0 as deletion of IBTK (6q14.1), UBE3A (11q22.1) and FBXO25 (8p23.3), and copy gain of ATF7 2 1 1 (12q13.13), UCHL5 (1q31.3), and KMT2A (11q23.3). Several CNA peaks, defined as the 2 1 2 smallest and most statistically significant region, included genes that were significantly mutated 2 1 3 ( Figure 2E) as well as other genes for which we detected mutations at lower frequencies that 2 1 4 were not significant by MutSig (POU2AF1, TP53BP1, FAS, PTEN) . Furthermore, for several of 2 1 5 these genes (ATM, B2M, BIRC3 and TNFRSF14), deletions were significantly co-associated 2 1 6 with mutations, suggesting that deletion and mutation are complementary mechanisms 2 1 7 contributing to biallelic inactivation. 2 1 8 2 1 9
Analyzing targets of translocations and CNAs added to enrichment of functional categories that 2 2 0 we observed within recurrently mutated genes, including chromatin modification (BCL11A) and 2 2 1 signaling (TCF4, PTEN). This was most prominently observed for genes with a role in apoptosis 2 2 2 and the cell cycle (CDKN2A, CDKN2B, FAS, RPL5, DFFB, MDM2, CDK6) and the UPS 2 2 3 (CUL4A, FBXO25, IBTK, RNF38, UBAP1, UBE3A, UBQLN1, UCHL5). Recurrently altered UPS 2 2 4 genes collectively promote or suppress the abundance or activity of proteins with roles in other 2 2 5 hallmark characteristics ( Figure 3A) . For example; SOCS1 51 , BIRC3 52 , DTX1 53,54 , IBTK 55 , 2 2 6 TRIM13 56 , TNFAIP3 53 and UBE3A 53 all inhibit the function of proteins with a role in important B-2 2 7 cell signaling pathways (Figure 3B) , thereby establishing a functional link between genetic 2 2 8 alteration of the UPS and deregulation of signaling and adding an additional layer to the 2 2 9 mechanisms by which B-cell receptor signaling is perturbed in B-NHL. The combined analysis of 2 3 0 mutations and structural alterations therefore identified large sets of genes that are targeted by 2 3 1 genetic alterations and collectively contribute to hallmark features that are commonly 2 3 2 deregulated across multiple B-NHL subtypes. 2 3 3 2 3 4 2 3 5
Disease-specific patterns of genetic alterations 2 3 6 Some interesting patterns of disease-specificity were obvious for both mutations and structural 2 3 7
alterations. We therefore formally tested the over-or under-representation of these events in 2 3 8 each of the 4 subtypes with >100 tumors (BL, DLBCL, FL, MCL), compared to all other tumors 2 3 9 in the study (Figure 4 ; Table S12 ). Using matched GEP data for a subset of cases (Table S1) , 2 4 0 we also tested the association between genetic alterations and molecularly-defined Burkitt's 2 4 1 lymphoma subtypes (n=154; Figure S6 -7, Table S13 ), as well as DLBCL cell of origin subtypes 2 4 2 (n=98; Figure S7 , Table S14 ). These analyses showed that the genetic alterations associated 2 4 3 with clinically-defined BL were also associated with molecularly-defined BL. Moreover, genetic 2 4 4 alterations that we and others have characterized as being over-represented in ABC-like DLBCL 2 4 5 such as CD79B mutation 57 , MYD88 mutation 58 and TCF4 copy gain 50 were significantly over-2 4 6
represented in this analysis also. 2 4 7 2 4 8
We observed some interesting patterns within hallmark characteristics that differ between 2 4 9 subtypes. For example, linker histone mutations were present in germinal center B (GCB)-cell 2 5 0 derived malignancies (BL, DLBCL, FL) at variable frequencies, but were largely absent from 2 5 1 MCL ( Figure S8 ). In contrast, mutations of genes encoding the H3K36 methyltransferases, 2 5 2 WHSC1 (aka MMSET/NSD2) and ASH1L, were frequent in MCL and largely absent from GCB-2 5 3 derived malignancies. We also noted that the SWI/SNF complex was perturbed in different ways 2 5 4 in different diseases (Figure 5) . Specifically, mutations of the SMARCA4 (aka. BRG1) 2 5 5 component of the ATPase module were significantly enriched in BL (24%) compared to other 2 5 6 subtypes (4%, Q-value<0.001), while mutations of the BCL7A component of the ATPase 2 5 7 module were significantly enriched in FL (11%) compared to other subtypes (4%, Q-2 5 8
represented in MCL compared to other subtypes, and were associated with this cluster. These 3 0 1 data show that different subtypes of B-NHL are defined by characteristic sets of co-associated 3 0 2 genetic alterations that affect multiple hallmarks. 3 0 3 3 0 4
Combinations of clonal genetic alterations define B-NHL subtypes 3 0 5
Our data have revealed statistical enrichment of individual genetic alterations in subtypes of B-3 0 6 NHL, and pairwise relationships between different genetic alterations that define clusters of 3 0 7 subtype-specific events. However, individual genetic alterations from disease-specific clusters 3 0 8 are also observed at variable frequencies in other B-NHL subtypes (Figure 6A) . We therefore 3 0 9 investigated whether the combination of multiple genetic alterations from each cluster, rather 3 1 0 than the presence or absence of a single alteration, were pathognomonic. By enumerating the 3 1 1 number of genetic alterations from each disease-specific cluster in each tumor, we found that 3 1 2 this was indeed the case. Specifically over half of all BL, FL and MCL tumors possessed ≥ 3 3 1 3 genetic alterations defined by their respective subtype-specific clusters (Figure 6) . These rates 3 1 4 were significantly higher than those observed in other diseases (Fisher P <0.001 for all 3 1 5 comparisons). For example, DLBCL and FL share many of the same recurrently mutated genes, 3 1 6 particularly when considering the C3/EZB subtype of DLBCL 3,4 . Thus, one or more FL cluster 3 1 7 alterations are found in 93% of FL tumors, but also in 54% of DLBCL tumors. However, FL 3 1 8 tumors have a significantly higher rate of accumulation of these mutations, with 68% of FL 3 1 9 tumors bearing ≥ 3 of the FL cluster alterations but only 18% of DLBCL tumors bearing ≥ 3 of 3 2 0 these genetic alterations (Fisher P < 0.001). This pattern is also conserved for the BL and MCL 3 2 1 clusters, for which the rate of acquiring ≥ 3 of the cluster alterations was significantly higher in BL 3 2 2 or MCL compared to other subtypes of B-NHL, respectively. Thus, B-NHL subtypes are defined 3 2 3 by the acquisition of multiple genetic alterations from subtype-associated clusters. 3 2 4 3 2 5
The co-association of multiple mutations may be suggestive of a clonal structure in which early 3 2 6 driver mutations are clonal and later driver mutations are present in sub-clones. We therefore 3 2 7 utilized ABSOLUTE (Table S16-18) to determine whether co-associated genetic alterations are 3 2 8 present at different clonal fractions, and could therefore be phased to create clonal hierarchies. 3 2 9
This analysis failed for a small subset of cases and could not be performed for X-linked genes 3 3 0 or translocations. However, it clearly revealed the majority of co-associated genetic alterations 3 3 1 were present at cancer cell fractions (CCF) >0.9, which is indicative that each mutation is 3 3 2 clonally represented in every cancer cell at the time of sampling. These data suggest that 3 3 3 combinations of mutations may therefore be required for effective expansion of lymphoma cells, 3 3 4 such that common precursor cells (CPCs) are not detectable within the clonal structure of the 3 3 5 clinically-detected tumor. These data therefore support the premise of epistatic interactions 3 3 6 between co-occurring genetic alterations in B-NHL. 3 3 7 3 3 8 DISCUSSION 3 3 9
By performing cross-sectional genomic profiling of a large cohort of tumors, we have defined 3 4 0 genes and functional hallmarks that are recurrently targeted by genetic alterations and showed 3 4 1 that combinations of genetic alterations are disease-defining features of B-NHL subtypes. Some 3 4 2 of the functional hallmarks that we identified have been previously appreciated in other 3 4 3 diseases, with a few exceptions. For example, the mutation of genes with roles in chromatin 3 4 4 modification are known to be a hallmark of FL 65 and we observed that over 90% of FLs 3 4 5 possessed mutations in one or more of the genes in this category. However, these mutations 3 4 6
were also observed in two thirds of BL and DLBCL tumors and nearly half of MCLs. There are 3 4 7 subtype-specific patterns of chromatin modifying gene alterations, such as those that we 3 4 8 described for H3K36 methylation in MCL and the unique patterns of SWI/SNF mutations across 3 4 9 GCB-derived B-NHLs. But we suggest that the genetic deregulation of chromatin modification 3 5 0 should be considered a general hallmark of B-NHL. In addition, we suggest that the 3 5 1 deregulation of BCL6 function and perturbation of the ubiquitin proteasome system are 3 5 2 hallmarks of B-NHL that require further investigation. We have highlighted some of the known 3 5 3 substrates of recurrently altered UPS genes from the literature, which shows the potential for 3 5 4 these genetic alterations to contribute to aberrant B-cell receptor signaling and proliferation. 3 5 5 However, many of the genes within these categories have not been functionally studied in the 3 5 6 context of B-cell lymphoma, which represents a significant gap in our understanding of disease 3 5 7 etiology. 3 5 8 3 5 9
The role of epistatic interactions between co-occurring genetic alterations is also an emerging 3 6 0 field that requires further investigation. These interactions are not uncommon in cancer 66 , but 3 6 1 our data show that they are pervasive and disease-defining features of the B-NHL genetic 3 6 2 landscape. Epistasis between co-associated genetic alterations identified in this study requires 3 6 3 formal validation in cell line and/or animal models. However, there are many instances in which 3 6 4 co-occurring genetic alterations that we observed have already been shown to cooperate in 3 6 5 lymphomagenesis. In addition to the aforementioned example of MYD88 and CD79B mutations, 3 6 6 transgenic mouse models of Ezh2 activating mutations or conditional deletion of Crebbp or 3 6 7
Kmt2d have shown that these events are not alone sufficient for lymphomagenesis 42,67-71 . We 3 6 8 and others have observed a co-association between the mutation of these genes and BCL2 3 6 9 translocations 16,21 , and the addition of a Bcl2 transgene to these murine models indeed 3 7 0 promoted lymphoma at a significantly higher rate than that observed with the Bcl2 transgene 3 7 1 alone 42,67-71 . These genetic alterations are therefore significantly more lymphomagenic in 3 7 2 combination than they are alone, which provides proof of principal that an epistatic relationship 3 7 3 exists between these co-occurring genetic alterations. Future studies focusing on other co-3 7 4
occurring mutations, such as MYC translocation and SMARCA4 mutation in BL, CREBBP and 3 7 5 KMT2D mutation in FL, TCF4 copy gain and MYD88 mutation in DLBCL, and ATM mutation and 3 7 6
RPL5 deletion in MCL, should therefore be performed to further explore these concepts and 3 7 7 define their underlying functional relationship. We suggest that combinations of genetic 3 7 8
alterations are likely to more accurately recapitulate the biology of B-NHL than single gene 3 7 9 models, and may reveal contextually different functional roles of genetic alterations depending 3 8 0 on the co-occurring events. 3 8 1 3 8 2
In conclusion, we have provided a framework of functional hallmarks and co-occurring genetic 3 8 3 alterations that are enriched within B-NHL subtypes. These genetic alterations likely represent 3 8 4 epistatic interactions that underpin the biology of these tumors, and represent an opportunity for 3 8 5 better understanding lymphoma etiology so that we can identify novel rational approaches for 3 8 6 therapeutic targeting of the underlying biology. 1199-1208, doi:10.1038/nm.3943 (2015) . The shaded region in B marks genes with significantly increased expression in tumors with 6 1 6 increased copy number compared to those without; the converse is true for the shaded region in 6 1 7 C. D) An oncoplot with DNA copy number losses and gains ranked according to their frequency 6 1 8
shows the distribution of structural alterations across tumors. E) Oncoplots show the overlap of 6 1 9 structural alterations and mutations that target the same genes. P-values are derived from a 6 2 0
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